Patrone F, Dallegri F, Pistoia V, Ghio R, Sacchetti C
Cancer. 1985 Apr 15;55(8):1668-72. doi: 10.1002/1097-0142(19850415)55:8<1668::aid-cncr2820550810>3.0.co;2-m.
Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the "immunomodulating" effect of the drug.
在体外以治疗浓度使用时，发现左旋咪唑能够恢复癌症患者中性粒细胞有缺陷的Fc受体活性。此外，该药物可防止癌症患者血清对正常中性粒细胞Fc受体功能的抑制。在7名癌症患者中，有6名在体内给予左旋咪唑（2.5毫克/千克/天，共3天）后，中性粒细胞Fc受体功能也得到了恢复。由于Fc受体功能在宿主防御机制（包括吞噬作用以及抗体依赖性细胞毒性）中发挥着核心作用，左旋咪唑恢复癌症患者有缺陷的中性粒细胞Fc受体功能的能力可能有助于该药物的“免疫调节”作用。
